Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a NaSSA presented as a tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mirzaten as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for major depressive disorder, a condition involving dysregulated serotonergic and noradrenergic pathways.

Major depressive disorder: reduces depressive symptoms and improves overall mood. Depressive symptoms in chronic illness: helps alleviate mood disturbances associated with long‑term disease. Adjunct therapy for treatment‑resistant depression: may be added when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or neutropenia - Severe hypersensitivity reactions (rash, angioedema) - Suicidal thoughts, especially early in therapy - Serotonin syndrome when combined with other serotonergic agents - Hepatotoxicity (rare liver enzyme elevations)

Before initiating therapy, clinicians should consider several safety aspects. - Hepatic function: assess liver status, adjust if severe impairment. - Weight monitoring: counsel patients about potential weight gain. - Elderly patients: start at low dose due to increased sedation risk. - Discontinuation: avoid abrupt stop to reduce withdrawal symptoms. - Bipolar disorder: monitor for emergence of mania. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increase serotonin syndrome risk. - CNS depressants (benzodiazepines, alcohol): additive sedation and respiratory depression. - CYP2D6 inhibitors (paroxetine, fluoxetine): may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: potential additive hypotensive effect. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Carbamazepine: may reduce mirtazapine concentrations, lowering efficacy.